Abeona Therapeutics Inc.
ABEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $3,500 | $1,414 | $3,000 |
| % Growth | -100% | 147.5% | -52.9% | – |
| Cost of Goods Sold | $2,907 | $1,605 | $450 | $0 |
| Gross Profit | -$2,907 | $1,895 | $964 | $3,000 |
| % Margin | – | 54.1% | 68.2% | 100% |
| R&D Expenses | $34,360 | $31,091 | $28,965 | $38,726 |
| G&A Expenses | $29,851 | $19,004 | $17,256 | $21,644 |
| SG&A Expenses | $29,851 | $19,004 | $17,256 | $21,644 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,907 | -$1,065 | $5,658 | $32,466 |
| Operating Expenses | $61,304 | $49,030 | $51,879 | $92,836 |
| Operating Income | -$64,211 | -$47,135 | -$50,915 | -$89,836 |
| % Margin | – | -1,346.7% | -3,600.8% | -2,994.5% |
| Other Income/Exp. Net | $477 | -$7,053 | $11,219 | $4,900 |
| Pre-Tax Income | -$63,734 | -$54,188 | -$39,696 | -$84,936 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$63,734 | -$54,188 | -$39,696 | -$84,936 |
| % Margin | – | -1,548.2% | -2,807.4% | -2,831.2% |
| EPS | -1.55 | -2.53 | -5.53 | -21.5 |
| % Growth | 38.7% | 54.2% | 74.3% | – |
| EPS Diluted | -1.55 | -2.53 | -5.53 | -21.5 |
| Weighted Avg Shares Out | 41,048 | 21,380 | 7,862 | 3,938 |
| Weighted Avg Shares Out Dil | 41,048 | 21,380 | 7,862 | 3,938 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,246 | $2,117 | $431 | $40 |
| Interest Expense | $4,208 | $418 | $736 | $3,656 |
| Depreciation & Amortization | $2,907 | $3,198 | $4,577 | $4,464 |
| EBITDA | -$56,619 | -$50,572 | -$34,383 | -$76,816 |
| % Margin | – | -1,444.9% | -2,431.6% | -2,560.5% |